Protalix BioTherapeutics, Inc. (PLX) is a publicly traded company in the Unknown sector. Across all available filings, 27 corporate insiders have executed 507 transactions totaling $79.5M, demonstrating a bearish sentiment with -$69.5M in net insider flow. The most recent transaction on Dec 19, 2025 involved a purchase of 56,000 shares valued at $101.4K.
No significant insider buying has been recorded for PLX in the recent period.
No significant insider selling has been recorded for PLX in the recent period.
Based on recent SEC filings, insider sentiment for PLX is bearish with an Insider Alignment Score of 6/100 and a net flow of -$69.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Protalix BioTherapeutics, Inc. (PLX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 27 insiders are actively trading PLX stock, having executed 507 transactions in the past 90 days. The most active insider is Eli Hurvitz (Executive), who has made 5 transactions totaling $13.9M.
Get notified when executives and directors at PLX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | Bashan Dror | Executive | Purchase | 56,000 | $1.81 | $101.4K | |
| Nov 18, 2025 | Bar-shalev Amos | Executive | Sale | 168 | $1.87 | $314 | |
| Sep 3, 2025 | Bashan Dror | Executive | Award | 195,000 | $N/A | $0 | |
| Sep 3, 2025 | Naos Yaron | Executive | Award | 25,000 | $N/A | $0 | |
| Sep 3, 2025 | Bar-shalev Amos | Executive | Award | 7,500 | $N/A | $0 | |
| Sep 3, 2025 | Shmuel Ben Zvi | Executive | Award | 7,500 | $N/A | $0 | |
| Sep 3, 2025 | Schwartz Aharon | Executive | Award | 7,500 | $N/A | $0 | |
| Sep 3, 2025 | F. Boudes Pol | Executive | Award | 7,500 | $N/A | $0 | |
| Sep 3, 2025 | A. Melincoff Gwen | Executive | Award | 7,500 | $N/A | $0 | |
| Sep 3, 2025 | Elze Christian | Executive | Award | 7,500 | $N/A | $0 | |
| Sep 3, 2025 | Forster Eliot | Executive | Award | 7,500 | $N/A | $0 | |
| Jun 10, 2025 | Schwartz Aharon | Executive | Purchase | 129,000 | $1.60 | $206.4K | |
| Sep 23, 2024 | Rubin Eyal | Executive | Award | 99,010 | $N/A | $0 | |
| Apr 1, 2024 | Bashan Dror | Executive | Award | 263,960 | $N/A | $0 | |
| Oct 19, 2023 | Bashan Dror | Executive | Purchase | 48,387 | $1.40 | $67.7K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 409 | $74.5M | 91.4% |
Purchase(P) | 24 | $5.0M | 6.1% |
Exercise(M) | 26 | $1.4M | 1.7% |
Payment(F) | 15 | $620.4K | 0.8% |
Award(A) | 27 | $0 | 0.0% |
Other(J) | 6 | $0 | 0.0% |
Insider selling pressure at Protalix BioTherapeutics, Inc. has increased, with 27 insiders executing 507 transactions across all time. Total sales of $74.5M significantly outpace purchases of $5.0M, resulting in a net outflow of $69.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.